May 27, 2026

The FDA has released a discussion paper to promote deeper and more productive engagements with stakeholders on potential flexibilities regarding the lot-level tracking requirements in the final rule, “Requirements for Additional Traceability Records for Certain Foods” (Food Traceability Rule). The discussion paper includes information and questions to help inform FDA’s engagements with stakeholders, including the upcoming virtual FDA-led public meeting on June 15th

The FDA encourages those attending and speaking at the public meeting to consider the topics in the discussion paper. The public meeting is free and open to the public, but registration is necessary to attend. If you would like to speak during the public comment period, please register by June 5. All others can register until June 14th. More information about registration and how to request to speak during the public comment period are available on our meeting page.

In addition to the public meeting, the FDA wants to provide all stakeholders with an opportunity to actively engage with the Agency on this topic. Therefore, all interested parties are encouraged to submit feedback on the discussion paper to https://www.regulations.gov, Docket No. FDA-2014-N-0053. Feedback does not need to cover every question that is asked in the document; you are encouraged to focus on whichever aspects of the discussion paper are of the most interest to you. To ensure that we can fully consider your feedback as we continue our stakeholder engagements and work to expeditiously identify flexibilities to help implement the lot-level tracking requirements of the Food Traceability Rule, please submit your feedback no later than July 15, 2026. 

For Additional Information

Contact us
Thank you for your interest in Garg Law PLLC.
Our commitment to understanding your regulatory questions and business goals, and helping you achieve results starts here.
If you are looking for representation on a new matter, please fill out the form below to request a free consultation. The form enables us to conduct a preliminary check for potential conflicts of interest and to determine if we can proceed with the free consultation.
Garg Law Global Icon

News & Insights

Get the latest news on FDA regulatory delivered straight to your inbox.